SOLIRIS (eculizumab): The first treatment specifically approved for PNH

Sign Up

Learn how OneSource can provide additional information about PNH and SOLIRIS.

Register here to become part of the SOLIRIS PNH community

Sign up to learn and share. As part of the SOLIRIS® (eculizumab) community, you'll receive regular updates, news and information. If you choose, you can also register to participate in market research activities.

  • Learn more about SOLIRIS as new research is published
  • Discover new PNH resources and support systems
  • Get ideas and tips for living with and managing PNH
  • Stay in touch with developments in PNH research and treatment

* indicates required field
Last Name:*  
First Name:*  
Address:*  
Address2:  
City:*  
State:*  
Zip Code:*  
At this time, SOLIRIS is commercially available only in the U.S.
Phone Number:*  
Email:*  
Confirm Email:*  
Please share your Physician Information with us so that we can send them important information and resources on PNH:
Physician Name:  
Physician Phone Number:  
Physician Email:  
 
  I'm interested in receiving ongoing information and updates about SOLIRIS and PNH.*

Please review our Terms and Conditions in addition to our Privacy Policy. By submitting your registration, you are agreeing to the terms of use and our Privacy Policy.
 
 

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.